Pancreatic Cancer Research

ResearcherUniversité de BordeauxActive in the last 2 years

Jean‐Frédéric Blanc

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-6172-9485; OpenAlex author ID A5082631947, A5111712866. Sources: OpenAlex.

Their work

Papers
23 (first author 2, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
89
Papers, trials and grants by year

2014: 1 paper · 2015: 2 papers · 2016: 1 paper · 2017: 1 paper · 2018: none · 2019: 4 papers · 2020: 2 papers · 2021: 2 papers · 2022: 1 paper · 2023: 1 paper · 2024: 3 papers · 2025: 4 papers · 2026: 1 paper

Papers 23

  1. Netrin1 blockade alleviates resistance to chemotherapy in pancreatic cancer. Co-author DOI 10.1038/s41586-026-10436-4↗
  2. Metallic trace elements in pancreatic tissue are associated with higher risk of pancreatic adenocarcinoma - METAPANDA study. Co-author DOI 10.1016/j.pan.2025.03.006↗
  3. CD40 agonist mitazalimab with mFOLFIRINOX in untreated metastatic pancreatic cancer: Biomarkers associated with outcomes from OPTIMIZE-1. Co-author DOI 10.1016/j.xcrm.2025.102407↗
  4. Real-world efficacy of nanoliposomal irinotecan in patients with advanced pancreatic cancer. Last author DOI 10.1186/s12885-025-15346-8↗
  5. Neoadjuvant FOLF(IRIN)OX Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Multicenter Randomized Noncomparative Phase II Trial (PANACHE01 FRENCH08 PROD… Co-author DOI 10.1200/jco-24-01378↗
  6. Predictive genomic and transcriptomic analysis on endoscopic ultrasound-guided fine needle aspiration materials from primary pancreatic adenocarcinoma: a prosp… Co-author DOI 10.1016/j.ebiom.2024.105373↗
  7. Olaparib as maintenance therapy in non resectable pancreatic adenocarcinoma associated with homologous recombination deficiency profile: A French retrospective… Co-author DOI 10.1016/j.ejca.2024.115051↗
  8. Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre… Co-author DOI 10.1016/s1470-2045(24)00263-8↗
  9. Efficacy and safety of abemaciclib alone and with PI3K/mTOR inhibitor LY3023414 or galunisertib versus chemotherapy in previously treated metastatic pancreatic… Co-author DOI 10.1002/cam4.6621↗
  10. Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial. Co-author DOI 10.1001/jamaoncol.2022.3829↗
  11. Early dose reduction/delay and the efficacy of liposomal irinotecan with fluorouracil and leucovorin in metastatic pancreatic ductal adenocarcinoma (mPDAC): A … Co-author DOI 10.1016/j.pan.2020.10.029↗
  12. Neoadjuvant treatment for borderline resectable pancreatic adenocarcinoma is associated with higher R0 rate compared to upfront surgery. Co-author DOI 10.1080/0284186x.2021.1944662↗
  13. Incidence of Venous Thromboembolism in Patients With Newly Diagnosed Pancreatic Cancer and Factors Associated With Outcomes. Co-author DOI 10.1053/j.gastro.2019.12.009↗
  14. Liposomal Irinotecan + 5-FU/LV in Metastatic Pancreatic Cancer: Subgroup Analyses of Patient, Tumor, and Previous Treatment Characteristics in the Pivotal NAPO… Co-author DOI 10.1097/mpa.0000000000001455↗
  15. FOLFIRINOX-based neoadjuvant chemoradiotherapy for borderline and locally advanced pancreatic cancer: A pilot study from a tertiary centre. Co-author DOI 10.1016/j.dld.2019.03.004↗
  16. Quality of life in metastatic pancreatic cancer patients receiving liposomal irinotecan plus 5-fluorouracil and leucovorin. Co-author DOI 10.1016/j.ejca.2018.09.029↗
  17. Liposomal irinotecan and 5-fluorouracil/leucovorin in older patients with metastatic pancreatic cancer - A subgroup analysis of the pivotal NAPOLI-1 trial. First author DOI 10.1016/j.jgo.2019.02.011↗
  18. Nomogram for Predicting Survival in Patients Treated with Liposomal Irinotecan Plus Fluorouracil and Leucovorin in Metastatic Pancreatic Cancer. Co-author DOI 10.3390/cancers11081068↗
  19. Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based … First author DOI 10.1038/bjc.2017.67↗
  20. Post-gemcitabine therapy for patients with advanced pancreatic cancer - A comparative review of randomized trials evaluating oxaliplatin- and/or irinotecan-con… Co-author DOI 10.1016/j.ctrv.2016.09.001↗
  21. FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort. Co-author DOI 10.1245/s10434-014-3898-9↗
  22. Pathologic Major Response After FOLFIRINOX is Prognostic for Patients Secondary Resected for Borderline or Locally Advanced Pancreatic Adenocarcinoma: An AGEO-… Co-author DOI 10.1245/s10434-015-4783-x↗
  23. Locally advanced pancreatic adenocarcinoma: reassessment of response with CT after neoadjuvant chemotherapy and radiation therapy. Co-author DOI 10.1148/radiol.14132914↗

Closest collaborators

The 25 strongest of 89 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Teresa Mercade Macarulla · 6 shared papers, 2019–2025 · strength 0.81
  2. Li‐Tzong Chen · 6 shared papers, 2017–2021 · strength 0.59
  3. Jens Thomas Siveke · 6 shared papers, 2017–2021 · strength 0.59
  4. Floris A. de Jong · 6 shared papers, 2016–2021 · strength 0.54
  5. Christophe Laurent · 5 shared papers, 2014–2025 · strength 0.54
  6. Bruce Belanger · 4 shared papers, 2019–2021 · strength 0.43
  7. David Tougeron · 2 shared papers, 2024–2025 · strength 0.38
  8. Emmanuel Mitry · 2 shared papers, 2024–2025 · strength 0.36
  9. Hans Prenen · 2 shared papers, 2024–2025 · strength 0.36
  10. Jean‐Luc Van Laethem · 2 shared papers, 2024–2025 · strength 0.36
  11. Karen Paula Geboes · 2 shared papers, 2024–2025 · strength 0.36
  12. Lorenzo Pilla · 2 shared papers, 2024–2025 · strength 0.36
  13. Yago Pico de Coaña · 2 shared papers, 2024–2025 · strength 0.36
  14. Roberto Pazo-Cid · 2 shared papers, 2024–2025 · strength 0.36
  15. Aurélien Lambert · 2 shared papers, 2024–2025 · strength 0.36
  16. Jaime Feliú · 2 shared papers, 2024–2025 · strength 0.36
  17. Philippe Alexandre Cassier · 2 shared papers, 2024–2025 · strength 0.36
  18. Anthony Turpin · 2 shared papers, 2024–2026 · strength 0.36
  19. Olivier Bouché · 2 shared papers, 2024–2026 · strength 0.36
  20. Andrea Wang‐Gillam · 4 shared papers, 2017–2020 · strength 0.35
  21. Jean‐Baptiste Bachet · 3 shared papers, 2015–2026 · strength 0.28
  22. Chung‐Pin Li · 2 shared papers, 2020–2023 · strength 0.27
  23. Sandra Mounicou · 1 shared paper, 2025 · strength 0.27
  24. Mireille Simon · 1 shared paper, 2025 · strength 0.27
  25. Tanios Bekaii‐Saab · 2 shared papers, 2019–2021 · strength 0.24

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.